Navigation Links
Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
Date:7/10/2008

d cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, such as statements preceded by, followed by or including the words "believe"; "expect"; "may"; "anticipate"; "projected"; "estimated"; "preliminary"; "suggest"; or "potential"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with the development of ipilimumab and other product candidates, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of antibody products in patients, uncertainties related to product manufacturing, risks associated with the enforceability of our patents, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission , including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that such development efforts will succeed or that developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
8. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
9. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
10. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
11. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 After 6 months of careful ... here - the new programme for the next Cool Chain ... our global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA and ... that is broad and yet specific, focused and yet accessible, ...
(Date:9/18/2014)... Calif. , Sept. 18, 2014   ... ), a biopharmaceutical company leading the discovery and ... it has initiated its ATHENA natural history of ... life-threatening genetic kidney disease with no approved therapy. ... natural decline of renal function markers such as ...
(Date:9/18/2014)... , Sept. 18, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that the ... Geert Cauwenbergh , will present at ... Conference on Wednesday, September 24, 2014 at ...
Breaking Medicine Technology:Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... MADISON, N.J., March 28, 2011 Quest Diagnostics Incorporated ... of diagnostic testing, information and services, announced today it ... subsidiary, Spark Acquisition Corporation, for all of the outstanding ... (Nasdaq: CRA ), one of the world,s ...
... (Nasdaq: VRUS ) today announced that it will ... Study of the Liver (EASL) on Saturday, April 2, 2011 ... Pharmasset,s progress on the programs that are the subject of ... a simultaneous webcast of this event via the internet, log ...
Cached Medicine Technology:Quest Diagnostics Commences Tender Offer for Acquisition of Celera 2Quest Diagnostics Commences Tender Offer for Acquisition of Celera 3Pharmasset to Webcast an Investor Event From the EASL Meeting 2Pharmasset to Webcast an Investor Event From the EASL Meeting 3
(Date:9/18/2014)... September 18, 2014 Relias Learning, the leader ... human services markets, today announced it has been named to ... private companies in America. , In the three-year period from ... up almost 2,000 spots on the Inc. 5000 list to ... , “The industries we serve continue to grow, and ...
(Date:9/18/2014)... PlatinumCode, a leading manufacturer and supplier ... the healthcare industry, announced earlier this month that ... their profits of the sale of eligible pink ... announcement, PlatinumCode has launched various marketing efforts to ... hospital labs with their popular “Pink Packs” of ...
(Date:9/18/2014)... “Awesome” is the way Emily W. describes her ... Internship Program at ARDX ( http://www.ardx.net ). Her ... as “Inspirational” and “Life-changing,” respectively. None of these ... be doing during their summer internship. Stacie was ... mindless tasks,” but, instead she was doing real, meaningful ...
(Date:9/18/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, 2014 (HealthDay ... stress disorder symptoms are almost three times more likely to ... The findings don,t prove a direct link between PTSD ... also possible that certain women are prone to food addiction ... research seems to add to existing evidence connecting PTSD to ...
(Date:9/18/2014)... 18, 2014 Fit Body Boot Camp ... fitness business in the country and its popularity, as both ... to grow enormously in 2014. , The company’s annual ... taking place in Costa Mesa, CA on September 26 and ... conferences yet. Founder Bedros Keuilian, who is also considered the ...
Breaking Medicine News(10 mins):Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:PlatinumCode Commits to Donating Five Percent of Profits from the sale of Pink Products to Support Breast Cancer Awareness 2Health News:ARDX Internship Helps Students to START on the Right Business Path 2Health News:ARDX Internship Helps Students to START on the Right Business Path 3Health News:ARDX Internship Helps Students to START on the Right Business Path 4Health News:PTSD Link to Food Addiction Seen in Report 2Health News:PTSD Link to Food Addiction Seen in Report 3Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 3
... Sales increase 73% over Third Quarter 2007, EMERYVILLE, ... ) today reported its financial results,for the three and ... of $12.2 million, or $0.21 per diluted share, for ... $0.6 million, or $0.01 per diluted share,in the same ...
... 6 Pharmos Corporation,(Nasdaq: PARS ) today reported results ... a net loss of $2.8 million, or $0.11 per,share, for ... $3.5 million,or $0.14 per share, in the third quarter 2007. ... The decrease in net loss for the third quarter ...
... and service levels were key reasons, says union,president, ... Paul N. Urick, R.Ph., announced today that the ... its Participating Employers Health,and Welfare Fund have agreed ... members pharmacy coverage through FutureScripts. UFCW Local,1776,s new ...
... room doctors, study says , , THURSDAY, Nov. 6 (HealthDay ... at the hands of peers, immediate one-on-one mentoring on ... their risk of becoming victims again, a new study ... for assault injuries -- including gunshot, knife and fist-fight ...
... mostly young children -- infected, bringing total to 79, CDC ... cases of people becoming infected with salmonella traced to dry ... , The outbreak, which started in 2006, marks the first ... source of the bacterial infection in people. , As of ...
... Company Reports Seventeenth Consecutive Quarter Of Growth In ... Inc.,(Nasdaq: GXDX ), a specialized laboratory services ... third quarter of 2008, which includes a,$2.5 million ... prior,periods. This compares to revenues of $16.2 million ...
Cached Medicine News:Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 2Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 3Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 4Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 5Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 6Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 7Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 8Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 9Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 10Health News:Pharmos Corporation Reports 2008 Third Quarter Results 2Health News:Pharmos Corporation Reports 2008 Third Quarter Results 3Health News:Pharmos Corporation Reports 2008 Third Quarter Results 4Health News:Pharmos Corporation Reports 2008 Third Quarter Results 5Health News:FutureScripts(R) Wins Business of UFCW Local 1776 for Pharmacy Benefits 2Health News:FutureScripts(R) Wins Business of UFCW Local 1776 for Pharmacy Benefits 3Health News:FutureScripts(R) Wins Business of UFCW Local 1776 for Pharmacy Benefits 4Health News:Counseling Can Combat Youth Violence 2Health News:Salmonella Outbreak Tied to Dry Dog Food Continues 2Health News:Salmonella Outbreak Tied to Dry Dog Food Continues 3Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 2Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 3Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 4Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 5Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 6Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 7Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 8Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 9Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 10
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
Medicine Products: